Highlights: Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Quis ipsum suspendisse ultrices gravida. Read more
LAuRA - Powered by PAT
Making future diagnostics affordable,
accessible and available anywhere
What We Do
LamdaGen develops and commercializes innovative detection technologies wherever and whenever time-critical detection is needed.
We focus on developing advanced testing systems that are simple, cost effective and globally available.
Our One Health (cdc.gov/onehealth) approach involves innovative systems for Human Clinical, Food & Water Safety and Animal Health.
Each unique system is built on the LAuRA™ Digital Detection platform, powered by PAT™.
The LAuRA Digitial Detection Platform, powered by PAT
See how Plasmonic Amplification Technology enables high sensitivity detection with the speed and precision to transform and improve Point of Care testing.
Features
Fast Results
High Sensitivity
Patented Technology
Easy to Integrate
Easy to Use
LAuRA POC System
The LAuRA Digital Detection platform that combines the speed and simplicity of current rapid lateral flow assays with the sensitivity and quantitation of microtiter plate assays.
The LAuRA POC System delivers laboratory quality results equivalent to gold standard ELISA’s in minutes rather than hours. LAuRA’s test procedure is simple and easy to use. Disposable cartridges can run single or dual tests simultaneously and deliver precise results in less than 15 minutes.
Leveraging the inherent properties of advanced nano-based plasmonics, the LAuRA immuno-based platform provides high sensitivity detection capabilities far exceeding those of existing rapid assays. The patented platform is flexible and scalable, enabling uniquely powerful detection systems ranging from small benchtops to handhelds to throughput.
Innovative LAuRA systems will be developed for applications in Human Health, Animal Health and Food & Water Safety.
What would you like to learn?
LAuRA, powered by PAT harnesses the unique properties of plasmonics to revolutionize diagnostic detection
See how LAuRA delivers results with speed, sensitivity and convenience like no other platform
LamdaGen is taking a One Health approach to improve the performance and accessibility of rapid testing
Latest News
Read More
This brief describes the optical properties of LamdaGen’s gold plasmonic sensor surfaces compared to the optical properties of gold (Au) colloids. As we will show, the plasmonic films are superior to gold colloidal solutions for biosensing. In fact, the optical properties of the plasmonic films match those of single Au nano-rods, one of the most sensitive techniques for biosensing as interrogated a single particle at a time. While biosensing at the single molecule level poses enormous challenges commercially, the patented manufacturing process of LamdaGen’s continuous nano-structured thin-films is highly reproducible, scalable and economic. Thus, the plasmonic films bring the benefits of the nanoscopic world into the commercial realm.
Read More
LamdaGen Corporation, a privately-owned company focused on the development and commercialization of plasmonic biosensor systems for Point of Care (POC) diagnostics, announced today the Indian Patent Office has granted and recorded patent 360405 titled ENZYMATIC ASSAY FOR LSPR which enables
Read More
MENLO PARK, CA, January 18, 2021— LamdaGen Corporation, a privately-owned company focused on the development and commercialization of plasmonic biosensor systems for Point of Care (POC) diagnostics, announced today the United States Patent and Trademark Office has given Official Notice
Read More
MENLO PARK, CA, January 18, 2021— LamdaGen Corporation, a privately-owned company focused on the development and commercialization of plasmonic biosensor systems for Point of Care (POC) diagnostics, announced today the United States Patent and Trademark Office has given Official Notice
Read More
MENLO PARK, CA, January 8, 2021— LamdaGen Corporation, a developer of plasmonic biosensor systems for diagnostics, announced the Japanese Patent Office has given Official Notice of Allowance to its patent application entitled MOBILE/WEARABLE DEVICES INCORPORATING LSPR SENSORS which enables high
Read More
The viral load of SARS-CoV-2 in patients charted as determined in hospital settings across several regions of the world.[1-4] In three studies, the pool includes a limited number patients with mild to moderate symptoms in hospitals,
Previous
Next
Interested in exploring partnerships with us?
LamdaGen is focused on providing innovative detection technologies wherever and whenever they are needed. Contact us to discuss how we can partner to improve testing globally.
